Hyperuricemia as a prognostic factor in pulmonary arterial hypertension

被引:59
作者
Bendayan, D
Shitrit, D
Ygla, M
Huerta, M
Fink, G
Kramer, MR
机构
[1] Rabin Med Ctr, Pulm Inst, IL-49100 Petah Tiqwa, Israel
[2] Rambam Med Ctr, Pulm Inst, Haifa, Israel
[3] IDF Epidemiol Sect, Tel Hashomer, Israel
关键词
uric acid; pulmonary arterial hypertension; prognostic marker;
D O I
10.1053/rmed.2003.1440
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary arterial hypertension is a malignant disease with a median survival of 3 years. Uric acid levels are elevated in severe heart failure and in states of hypoxemia. Early data suggest a correlation between hyperuricemia and severe pulmonary arterial hypertension. We studied 29 patients with pulmonary arterial hypertension diagnosed and treated between 1998 and 2001. Clinical characteristics (6 min walk test and New York Heart Association class) and hemodynamic parameters (pulmonary artery pressure, pulmonary vascular resistance and cardiac output) were evaluated and correlated to uric acid level in a retrospective study. Uric acid levels correlated positively with New York Heart Association class (r=0.66, P < 0.001) and negatively with 6 min walk test (r=-0.35, P=0.03). Uric acid levels were higher in patients who died than in patients who survived at the end of the follow-up period (8.8 vs. 5.7 mg/dl, P=0.001). This study shows that uric acid levels are elevated in severe pulmonary arterial hypertension and can be used as a prognostic marker of disease severity. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:130 / 133
页数:4
相关论文
共 13 条
[1]  
ANTON MA, 1989, MED CLIN-BARCELONA, V328, P330
[2]   Urinary cGMP concentrations in severe primary pulmonary hypertension [J].
Bogdan, M ;
Humbert, M ;
Francoual, J ;
Claise, C ;
Duroux, P ;
Simonneau, G ;
Lindenbaum, A .
THORAX, 1998, 53 (12) :1059-1062
[3]   OVERNIGHT URINARY URIC-ACID - CREATININE RATIO FOR DETECTION OF SLEEP HYPOXEMIA - VALIDATION-STUDY IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE AND OBSTRUCTIVE SLEEP-APNEA BEFORE AND AFTER TREATMENT WITH NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE [J].
BRAGHIROLI, A ;
SACCO, C ;
ERBETTA, M ;
RUGA, V ;
DONNER, CF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (01) :173-178
[4]   Plasma markers of endothelial dysfunction in pulmonary hypertension [J].
Cella, G ;
Bellotto, F ;
Tona, F ;
Sbarai, A ;
Mazzaro, G ;
Motta, G ;
Fareed, J .
CHEST, 2001, 120 (04) :1226-1230
[5]   METABOLIC BASIS FOR DISORDERS OF PURINE NUCLEOTIDE DEGRADATION [J].
FOX, IH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1981, 30 (06) :616-634
[6]   Treatments for severe pulmonary hypertension [J].
Higenbottam, T ;
Stenmark, K ;
Simonneau, G .
LANCET, 1999, 353 (9150) :338-340
[7]   Hyperuricaemia in patients with right or left heart failure [J].
Hoeper, MM ;
Hohlfeld, JM ;
Fabel, H .
EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (03) :682-685
[8]  
Leyva F, 1997, EUR HEART J, V18, P858
[9]   Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [J].
McLaughlin, VV ;
Genthner, DE ;
Panella, MM ;
Rich, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :273-277
[10]   Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension - Comparison with cardiopulmonary exercise testing [J].
Miyamoto, S ;
Nagaya, N ;
Satoh, T ;
Kyotani, S ;
Sakamaki, F ;
Fujita, M ;
Nakanishi, N ;
Miyatake, K .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (02) :487-492